Rockenstein E - Search Results

1

Next-generation active immunization approach for synucleinopathies: implications for Parkinson's disease clinical trials.

Mandler M, Valera E, Rockenstein E, Weninger H, Patrick C, Adame A, Santic R, Meindl S, Vigl B, Smrzka O, Schneeberger A, Mattner F, Masliah E. Mandler M, et al. Among authors: rockenstein e. Acta Neuropathol. 2014;127(6):861-79. doi: 10.1007/s00401-014-1256-4. Epub 2014 Feb 14. Acta Neuropathol. 2014. PMID: 24525765 Free PMC article.

2

In vitro synaptotrophic effects of Cerebrolysin in NT2N cells.

Mallory M, Honer W, Hsu L, Johnson R, Rockenstein E, Masliah E. Mallory M, et al. Among authors: rockenstein e. Acta Neuropathol. 1999 May;97(5):437-46. doi: 10.1007/s004010051012. Acta Neuropathol. 1999. PMID: 10334480

3

Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders.

Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Takeda A, Sagara Y, Sisk A, Mucke L. Masliah E, et al. Among authors: rockenstein e. Science. 2000 Feb 18;287(5456):1265-9. doi: 10.1126/science.287.5456.1265. Science. 2000. PMID: 10678833

4

Genetically altered transgenic models of Alzheimer's disease.

Masliah E, Rockenstein E. Masliah E, et al. Among authors: rockenstein e. J Neural Transm Suppl. 2000;59:175-83. doi: 10.1007/978-3-7091-6781-6_20. J Neural Transm Suppl. 2000. PMID: 10961430 Review.

5

beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease.

Masliah E, Rockenstein E, Veinbergs I, Sagara Y, Mallory M, Hashimoto M, Mucke L. Masliah E, et al. Among authors: rockenstein e. Proc Natl Acad Sci U S A. 2001 Oct 9;98(21):12245-50. doi: 10.1073/pnas.211412398. Epub 2001 Sep 25. Proc Natl Acad Sci U S A. 2001. PMID: 11572944 Free PMC article.

6

Altered expression of the synuclein family mRNA in Lewy body and Alzheimer's disease.

Rockenstein E, Hansen LA, Mallory M, Trojanowski JQ, Galasko D, Masliah E. Rockenstein E, et al. Brain Res. 2001 Sep 28;914(1-2):48-56. doi: 10.1016/s0006-8993(01)02772-x. Brain Res. 2001. PMID: 11578596

7

beta-Synuclein inhibits alpha-synuclein aggregation: a possible role as an anti-parkinsonian factor.

Hashimoto M, Rockenstein E, Mante M, Mallory M, Masliah E. Hashimoto M, et al. Among authors: rockenstein e. Neuron. 2001 Oct 25;32(2):213-23. doi: 10.1016/s0896-6273(01)00462-7. Neuron. 2001. PMID: 11683992 Free article.

8

Differential neuropathological alterations in transgenic mice expressing alpha-synuclein from the platelet-derived growth factor and Thy-1 promoters.

Rockenstein E, Mallory M, Hashimoto M, Song D, Shults CW, Lang I, Masliah E. Rockenstein E, et al. J Neurosci Res. 2002 Jun 1;68(5):568-78. doi: 10.1002/jnr.10231. J Neurosci Res. 2002. PMID: 12111846

9

Development of a new treatment for Alzheimer's disease and Parkinson's disease using anti-aggregatory beta-synuclein-derived peptides.

Windisch M, Hutter-Paier B, Rockenstein E, Hashimoto M, Mallory M, Masliah E. Windisch M, et al. Among authors: rockenstein e. J Mol Neurosci. 2002 Aug-Oct;19(1-2):63-9. doi: 10.1007/s12031-002-0012-8. J Mol Neurosci. 2002. PMID: 12212795

10

Effects of Cerebrolysin on amyloid-beta deposition in a transgenic model of Alzheimer's disease.

Rockenstein E, Mallory M, Mante M, Alford M, Windisch M, Moessler H, Masliah E. Rockenstein E, et al. J Neural Transm Suppl. 2002;(62):327-36. J Neural Transm Suppl. 2002. PMID: 12456076

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

217 results

Search Page

Filters